Capital Fund Management S.A. Grows Stock Holdings in TransMedics Group, Inc. $TMDX

Key Points

• Capital Fund Management S.A. increased its holdings in TransMedics Group by 100.4%, acquiring an additional 126,414 shares, bringing its total ownership to 252,294 shares valued at approximately $16.97 million.
• Multiple institutional investors significantly increased their positions in TransMedics Group during the fourth quarter, with Dimensional Fund Advisors LP raising its stake by 1,565.5%.
• Analysts have expressed positive sentiment towards TransMedics Group, with several raising their price targets; Morgan Stanley set its target at $123.00 while Canaccord Genuity Group increased theirs to $142.00.

Capital Fund Management S.A. boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 100.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 252,294 shares of the company's stock after acquiring an additional 126,414 shares during the period. Capital Fund Management S.A. owned 0.75% of TransMedics Group worth $16,974,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Braidwell LP acquired a new position in TransMedics Group in the fourth quarter valued at approximately $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in TransMedics Group by 16.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock valued at $56,307,000 after acquiring an additional 128,474 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in TransMedics Group by 73.0% in the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock valued at $51,635,000 after acquiring an additional 349,403 shares during the last quarter. Emerald Advisers LLC lifted its holdings in TransMedics Group by 22.4% in the first quarter. Emerald Advisers LLC now owns 454,794 shares of the company's stock valued at $30,599,000 after acquiring an additional 83,083 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in TransMedics Group by 2.1% in the first quarter. Northern Trust Corp now owns 361,963 shares of the company's stock valued at $24,353,000 after acquiring an additional 7,341 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Down 0.4%

NASDAQ:TMDX traded down $0.43 during trading hours on Tuesday, hitting $114.55. The company's stock had a trading volume of 279,167 shares, compared to its average volume of 1,321,102. The stock has a market capitalization of $3.90 billion, a P/E ratio of 59.24 and a beta of 2.09. The stock has a fifty day moving average of $121.11 and a 200-day moving average of $102.00. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.00.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.TransMedics Group's revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Activity

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider owned 13,955 shares of the company's stock, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 7.00% of the company's stock.

Analysts Set New Price Targets

TMDX has been the topic of a number of recent analyst reports. Wall Street Zen upgraded TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Canaccord Genuity Group upped their price target on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Piper Sandler restated an "overweight" rating and set a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Morgan Stanley upped their price target on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Finally, Oppenheimer upped their price target on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $123.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.